Other safety alerts
|
| |
| DH receives notification from GSK regarding the discontinuation in local supply of "Cervarix Vaccine (Pre-Filled Syringe)" (HK-56180), a bivalent HPV vaccine, by March 2021 |
| |
On 4 February 2021, GlaxoSmithKline Limited (GSK) notified the Department of Health (DH) about the discontinuation in local supply of a bivalent Human Papillomavirus (HPV) vaccine, namely "Cervarix Vaccine (Pre-Filled Syringe)" (HK-56180), by March 2021 because its local demand has reduced significantly.
According to GSK, letters will be issued to customers who enquire to order the HPV vaccine notifying them about this planned discontinuation of supply.
The local supply of another HPV vaccine registered by Merck Sharp & Dohme (Asia) Limited (MSD), "Gardasil Vaccine Inj (pre-filled syringe)" (HK-54935) (a 4-valent HPV vaccine), was also discontinued earlier at the end of 2018 due to significant reduction in local demand. Related news was posted on the Drug Office website http://www.drugoffice.gov.hk/eps/news/../32979.html on 13 September 2018.
At present, there are three types of HPV vaccines registered in Hong Kong, including "Cervarix" (HK-56180) (i.e. bivalent HPV vaccine) registered by GSK; "Gardasil" (i.e. 4-valent HPV vaccine) [presented in two injectable forms (HK-54934 and HK-54935)] and "Gardasil 9" [presented in two forms of pre-filled syringe (HK-64239 and HK-66391)] (i.e. 9-valent HPV vaccine), both registered by MSD. They are all prescription medicines.
DH will maintain close liaison with the HPV vaccine suppliers to monitor their supply situation. Members of public should contact their healthcare professionals for seeking appropriate advice and vaccination recommendation if and when necessary.
Ends/Tuesday, Feb 9, 2021
Issued at HKT 16:00 |
| |
